A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients (PHACS)

PrintE-mail
Title A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients (PHACS)
Contact HM
Principal Investigator Renuka Iyer, MD
Study Number 202711
Phase1
Summary Venous Thrombus Embolism is an increasingly frequent  complication of cancer and anti-cancer therapies.  It is associated with increased mortality and other significant adverse consequences.  Risk factors for VTE in the cancer populations with the use of thromboprophylaxis.  However, prophylaxis studies in the ambulatory cancer population have been largely unsuccessful primarily because of low event rates in patients chosen on the basis of one or two risk factors.  The use of a validated risk model that incorporates multiple factors to identify high-risk patients represents a novel way to identify an appropriate population for prophylaxis.  This study will evaluate the safety and efficacy of prophylaxis in a high-risk subgroup of cancer patients identified by a validated risk model.  Correlative studies will evaluate the benefit of tissue factor as a predictive biomarker of VTE.
Eligibility
  •  A histologic diagnosis of malignancy. 
  • Age 18 years or older. 
  • Provide written informed consent. 
  • A risk score for VTE greater than or equal to 3 [assign score of 2 for very high risk sites of cancer (stomach, pancreas), score of 1 for high risk site (lung, lymphoma, gynecologic, bladder, testicular) and score of 0 for all other sites]. 
  • A planned initiation of new systemic chemotherapy regimen (including patients starting on first chemotherapy or patients previously treated but starting on a new regimen).
For more information about the clinical study go to Clinicaltrial.Gov